China Pharma Holdings (CPHI) AI Stock Analysis

• Market Cap: $4.76M
• Dividend Yield: N/A
• Average Volume (3M): 100.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.46
• Revenue Growth: -33.10%
• EPS Growth: 71.37%
• Country: US
• Employees: 224
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.07
• Shares Outstanding: 3,262,002
• 10 Day Avg. Volume: 154,517
• 30 Day Avg. Volume: 100,277
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 2.45
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: >-0.01
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $1.50
• Price Target Upside: 2.74% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 39 Underperform
• Price Target: $1.50 ▲(2.74% Upside)

The overall stock score is primarily impacted by significant financial instability, with negative profitability, high leverage, and cash flow issues being major concerns. The technical analysis shows a slightly bearish trend, while negative P/E ratio and lack of dividend yield highlight valuation challenges. The absence of earnings call and corporate events data means these factors were not considered.

China Pharma Holdings Business Overview & Revenue Model

Company Description

China Pharma Holdings, Inc. (CPHI) is a pharmaceutical company engaged in the development, manufacture, and marketing of a wide range of pharmaceutical products, particularly focusing on prescription drugs, over-the-counter medications, and health supplements. The company operates primarily in the Chinese market but also aims to expand its presence internationally. CPHI specializes in various therapeutic areas, including cardiovascular diseases, infectious diseases, and gastrointestinal disorders, leveraging its proprietary technologies to enhance drug formulations and delivery systems.

How the Company Makes Money

China Pharma Holdings generates revenue primarily through the sale of its pharmaceutical products, which include prescription medications and over-the-counter drugs. The company has established partnerships with healthcare providers and distributors, allowing it to broaden its market reach and enhance sales. Key revenue streams include direct sales to hospitals and clinics, distribution agreements with pharmaceutical wholesalers, and export sales to international markets. Additionally, CPHI may benefit from government subsidies and grants aimed at promoting domestic pharmaceutical research and development, further contributing to its earnings.

China Pharma Holdings Financial Statement Overview

Summary

China Pharma Holdings faces substantial financial challenges across income, balance sheet, and cash flow statements. Persistent losses, high leverage, and negative cash flows indicate operational and financial instability. Strategic improvements are necessary to enhance profitability, reduce debt reliance, and stabilize cash flows.

Income Statement

The income statement exhibits significant challenges, with negative gross profit and net income margins over the past years, indicating ongoing losses. Revenue growth is erratic, and both EBIT and EBITDA margins remain negative, reflecting operational inefficiencies and cost management issues.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, indicating potential leverage risks. Return on equity is negative due to persistent losses. However, the equity ratio is moderately healthy, suggesting some asset stability despite financial distress.

Cash Flow

Cash flow analysis highlights a negative free cash flow and operating cash flow, indicating cash constraints. The ratios of operating and free cash flow to net income are unfavorable, emphasizing cash management difficulties and potential liquidity issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.53M	7.01M	8.10M	9.64M	10.87M
Gross Profit	-1.99M	-281.08K	-493.92K	349.27K	1.95M
EBITDA	-1.96M	8.44K	-837.69K	230.34K	106.85K
Net Income	-4.74M	-3.08M	-10.22M	-3.94M	-3.16M
Balance Sheet
Total Assets	14.89M	16.47M	17.78M	22.65M	21.12M
Cash, Cash Equivalents and Short-Term Investments	626.88K	1.42M	2.03M	4.86M	957.65K
Total Debt	3.59M	4.63M	8.76M	12.49M	7.43M
Total Liabilities	7.14M	9.01M	13.49M	16.63M	13.11M
Stockholders Equity	7.75M	7.45M	4.29M	6.02M	8.00M
Cash Flow
Free Cash Flow	-758.08K	-711.20K	-811.51K	-687.89K	-909.57K
Operating Cash Flow	-466.36K	-699.69K	-409.55K	-249.84K	-42.26K
Investing Cash Flow	-291.72K	-11.52K	-401.96K	-438.06K	-867.31K
Financing Cash Flow	27.35K	73.14K	-1.77M	4.60M	624.18K

China Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPHI, the sentiment is Negative. The current price of 1.46 is below the 20-day moving average (MA) of 1.63, below the 50-day MA of 1.69, and below the 200-day MA of 1.99, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 36.78 is Neutral, neither overbought nor oversold. The STOCH value of 41.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CPHI.

China Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.76%	-2.28%
SNOA	51 Neutral	$8.66M	―	-78.73%	―	17.43%	75.52%
EVOK	46 Neutral	$7.67M	―	-152.92%	―	89.89%	85.54%
UPC	45 Neutral	$2.01M	―	2.66%	―	-27.81%	―
SBFM	42 Neutral	$6.88M	―	-25.65%	―	19.22%	98.73%
CPHI	39 Underperform	$4.76M	―	-52.05%	―	-33.10%	71.37%

China Pharma Holdings Corporate Events

China Pharma Holdings Announces Reverse Stock Split

On April 4, 2025, China Pharma Holdings announced a 1-for-10 reverse stock split set to take effect on April 15, 2025. This move, authorized by the Board and stockholders, will consolidate every 10 shares into one, affecting all shareholders uniformly without altering their percentage interest in the company.